UMB Bank N A MO Has $292,000 Holdings in Davita Inc (NYSE:DVA)

UMB Bank N A MO lifted its holdings in Davita Inc (NYSE:DVA) by 6.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,183 shares of the company’s stock after acquiring an additional 309 shares during the quarter. UMB Bank N A MO’s holdings in Davita were worth $292,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Oregon Public Employees Retirement Fund boosted its holdings in shares of Davita by 0.5% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 36,727 shares of the company’s stock worth $1,994,000 after acquiring an additional 185 shares in the last quarter. Securian Asset Management Inc lifted its holdings in Davita by 1.7% during the 1st quarter. Securian Asset Management Inc now owns 13,178 shares of the company’s stock worth $715,000 after buying an additional 217 shares in the last quarter. Piedmont Investment Advisors Inc. lifted its holdings in Davita by 3.3% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 6,974 shares of the company’s stock worth $379,000 after buying an additional 225 shares in the last quarter. Creative Planning lifted its holdings in Davita by 3.6% during the 2nd quarter. Creative Planning now owns 7,231 shares of the company’s stock worth $407,000 after buying an additional 250 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in Davita by 2.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 11,337 shares of the company’s stock worth $637,000 after buying an additional 251 shares in the last quarter. 89.57% of the stock is currently owned by institutional investors and hedge funds.

NYSE:DVA traded down $0.74 during trading hours on Wednesday, hitting $58.65. 98,081 shares of the stock were exchanged, compared to its average volume of 1,961,263. The company’s 50 day moving average is $57.86. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10. The firm has a market capitalization of $9.46 billion, a P/E ratio of 16.49, a P/E/G ratio of 0.57 and a beta of 1.59. Davita Inc has a twelve month low of $43.40 and a twelve month high of $79.11.



Davita (NYSE:DVA) last posted its quarterly earnings results on Thursday, August 1st. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.12. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.86 billion. Davita had a return on equity of 14.67% and a net margin of 1.21%. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.05 EPS. On average, research analysts anticipate that Davita Inc will post 4.74 earnings per share for the current fiscal year.

Several research analysts have issued reports on DVA shares. William Blair reaffirmed a “buy” rating on shares of Davita in a report on Thursday, June 20th. TheStreet raised Davita from a “c+” rating to a “b-” rating in a report on Wednesday, July 24th. Zacks Investment Research raised Davita from a “sell” rating to a “hold” rating in a report on Friday, May 10th. ValuEngine raised Davita from a “sell” rating to a “hold” rating in a report on Monday, July 22nd. Finally, Deutsche Bank reduced their price objective on Davita from $68.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Davita currently has a consensus rating of “Hold” and a consensus price target of $67.06.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Arbitrage

Institutional Ownership by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.